This program applies to behavior-based learning methods to improve overall health outcomes in patients with arthritis and fibromyalgia pain syndromes. After participating in this program, clinicians will be better able to diagnose and evaluate treament options; identify important patient issues, including treatment expectations and adherence, comorbidities, and how to communicate the risks and benefits with analgesics; and appraise the clinical trial evidence to safely, effectively, and confidently care for patients with arthritis or fibromyalgia pain syndromes.

• Discuss the relative CV and GI risk of nonsteroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective inhibitors
• Identify an individual patient’s level of potential CV or GI risk based on family history, medical history, and primary complaint(s)
• Weigh the benefits of treating arthritis pain against the risk therapy may pose to patients with some level of CV or GI risk
• Counsel patients to help them better understand their own level of treatment benefit and risk, and make informed decisions about their pain relief therapy
• Explain the evolution in understanding of fibromyalgia as a sensory syndrome
• List the various approaches which can be undertaken to relieve chronic pain caused by fibromyalgia

Lesley M. Arnold, MD
Associate Professor of Psychiatry
Director, Women's Health Research Program
University of Cincinnati College of Medicine
Cincinnati, OH

Jeffrey L. Boone, MD, MS
Consultant in Preventive Cardiology and
Cardiometabolic Risk for the
NFL Alumni Association and the
Denver Broncos Football Club
Denver, CO

Lee S. Simon, MD
Asscoiate Clinical Professor of Medicine
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston, MA

Dr. Arnold has received grants or research support from Eli Lilli and Company, Pfizer Inc., Cypress Biosciences, Inc., Wyeth Pharmaceuticals, Sanofi-Aventis, Boehringer-Ingelheim, Allergan, and Forecast Laboratories. She is a consultant for Eli Lilly and Company, Pfizer Inc., Cypress Biosciences, Inc. ,Wyeth Pharmaceuticals, Sanofi-Aventis, Boehringer-Ingelheim, Sepracor, Allergan, Forest Laboratories, and Vivus, Inc. Dr. Arnold is a member of the Speakers' Burueau of Eli Lilly and Company and Pfizer, Inc.

Dr. Boone is a member of the Speakers' Bureau for Abbott Laboratories, Novartis Corporation, Pfizer Inc., King Pharmaceuticals, Inc., Liposcience, Inc., and Kos Pharmaceuticals, Inc.

Dr. Simon is a consultant for AAI Pharma, Affinergy, AstraZeneca, Abraxxis, Alpha Rx, Nuvo/Dimethaid, Neopharm, Pfizer Inc., Novartis, PLx Pharma, Hisamatsu, LAB Pharma, Dr. Reddy's, Biosense, Avanir, Cerimon, Leerink Swann, Alimera, Nomura, Luxor, Paraexel, Nitec, Bayer, Combinatoryx, Rigel, Chelsea, Regeneron, Gynelabs, Cypress, SNBL, Skyepharma, Proctor and Gamble, Savient, Solace, Puretechventures, Puretech Development, White Mountain Pharma, TAP, Abbott Laboratories, Cell Therapeutics, Omeros, Jazz, Schwarz, Proethic, Takeda, Teva, Zydus, Proprius, Savient, Alder, Cure, Cellegy, Chemocentryx, McKesson, Diobex, Sepracor, Purdue Pharma, Serono, Coley, Medimmune, Altea, Neuromed, Polymerix, Talagan, Tigenix, and Millenium Pharmaceuticals.